Strategic Partnerships Recent collaboration with Molecular Partners to develop Radio-DARPin therapeutics suggests a readiness to engage in joint development and manufacturing initiatives for isotope-related components, signaling opportunities for supply agreements, custom sourcing, and contract manufacturing services.

Healthcare Footprint Operating as a hospital and health care focused isotope products provider with a sizable employee base and a presence in California indicates potential for regional sales expansion, on-site service offerings, and training programs for clinical radiopharmacy teams.

Industry Visibility Participation in high-profile events such as the JP Morgan Healthcare Conference demonstrates active customer outreach and branding opportunities; align outreach with investors and large hospital networks seeking isotope diagnostics and therapy components.

Growth Through Acquisition Acquisition of Tecnonuclear SA signals a growth trajectory and integration of broader Latin American and international capabilities, opening doors for cross-border distribution, regulatory support, and expanded product portfolios in radiopharmacy.

Financial Scale Revenue in the mid-range of tens of millions and a mid-sized team position the company as a credible mid-market partner for mid- to large-scale projects, enabling targeted proposals for supply contracts, long-term pricing agreements, and volume-based incentives.